Arizona 2026 Regular Session

Arizona House Bill HB2415

Introduced
1/15/26  
Report Pass
2/4/26  
Report Pass
2/9/26  
Engrossed
2/26/26  
Report Pass
3/25/26  

Caption

Kratom products; narcotic drugs

Impact

The enactment of HB2415 would have a significant impact on state laws governing the sale of kratom products. By mandating strict labeling practices, it aims to inform consumers about the ingredients and potential risks associated with kratom consumption. The restrictions on marketing and distribution, particularly to minors, seek to mitigate health risks and protect vulnerable populations. Furthermore, the bill establishes penalties for violations, categorizing offenses ranging from misdemeanors to felonies depending on the nature of the infraction, thereby enhancing the legal framework surrounding these products.

Summary

House Bill 2415, also known as the Kratom Products Act, aims to regulate the sale and distribution of kratom products within Arizona. The bill defines kratom products as any product containing parts of the Mitragyna speciosa plant, commonly used for its stimulant and sedative effects. The legislation includes provisions for labeling requirements, restricting the sale to individuals over twenty-one years of age, and preventing sales near schools and child care facilities. Key amendments to existing statutes under this bill outline the responsibilities of manufacturers and retailers in ensuring product safety and consumer awareness.

Sentiment

The sentiment surrounding HB2415 appears to be mixed. Proponents support the regulation as a necessary step toward consumer safety and public health, emphasizing the importance of informed consumption in light of growing concerns about kratom's effects. Conversely, opponents argue that excessive regulation could hinder consumer access to these products, which some individuals rely on for various reasons, including pain management and anxiety relief. This debate illustrates a tension between public health initiatives and personal freedoms in consumer choice.

Contention

Notable points of contention include discussions about the labeling requirements, which mandate clear disclosure of active ingredients such as mitragynine and 7-hydroxymitragynine. Critics of the bill raise concerns that such specifications might limit product availability or increase costs for consumers. Additionally, the enforcement provisions spark debate regarding the feasibility and fairness of penalties imposed on retailers, especially smaller businesses that may struggle to comply with the stringent regulations. As the bill progresses through legislative channels, these issues are likely to remain focal points in discussions around its implications.

Companion Bills

No companion bills found.

Previously Filed As

AZ SB1622

Narcotic drugs; definition

AZ SB1621

Narcotic drugs; death; sentence enhancement

AZ HB2798

Narcotic injection sites; zoning; prohibition

AZ HB2778

Luxury tax; nicotine; vapor; products

AZ SB1702

Hemp-derived products; regulation

AZ HB2823

AHCCCS; nonopioid drugs; formulary

AZ HB2012

Emergency use products; employers; prohibition

AZ SB1272

Vapor products; regulation; directory

AZ HB2739

Food products; cultivated cells; labeling

AZ HB2917

Drug paraphernalia; repeal

Similar Bills

No similar bills found.